S-Docs Achieves FedRAMP® High Authorization, Meeting IL5 Requirements
S-Docs is now the only document generation and e-Signature AppExchange Vendor with IL5 attestation on Salesforce Government Cloud
FedRAMP is the
"We're proud to serve government organizations like the U.S. Department of Veterans Affairs, the U.S. Department of Defense, and the U.S. Food and Drug Administration," said Brian Stimplf, CEO of S-Docs. "This attestation underscores S-Docs' focus on trust, data privacy, and compliance. Ultimately, it highlights our commitment to helping government and other security-conscious teams accelerate the path to mission success through secure, efficient document automation and e-Signature."
With this attestation, S-Docs can expand its footprint with
"Achieving FedRAMP authorization reflects S-Docs' ability to meet rigorous security and governance requirements for regulated environments," said
To learn more visit www.sdocs.com/trust.
About S-Docs
S-Docs is a document operations platform that helps thousands of organizations — from small shops to global enterprises — scale smarter. It enables any business to effortlessly create and sign critical documents through intuitive, secure document automation and e-Signature solutions. S-Docs goes beyond simplifying workflows — it drives process transformation.
Thousands of organizations in every industry rely on S-Docs to win faster, amplify productivity, and delight customers at every opportunity. Built with your unique needs in mind, S-Docs seamlessly connects to the processes that power your business so you can start streamlining the way your team creates, manages, and shares information instantly — and realize operational efficiency faster.
Media Contact
[email protected]
View original content:https://www.prnewswire.com/news-releases/s-docs-achieves-fedramp-high-authorization-meeting-il5-requirements-302670854.html
SOURCE S-Docs
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Basware Customers Representing $1.4 Trillion in Revenue Say Trust is the Next Test for Enterprise AI
- Riboscience Presents Phase 1a/b Overall Survival Data for ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination Therapy in Advanced Solid Tumors and Late-Line CRC
- CM Vantage Names Amy Finnegan Managing Director, Casualty
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share